SCHEMBL3873202

SCHEMBL3873202

Clc1[c]c(Cl)cc(-c2cccc(Cl)c2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.42
CNR2 P34972 7/20 0.41
NOTUM Q6P988 1/20 0.38
IDO1 P14902 1/20 0.38
CNR1 P21554 1/20 0.37
TSHR P16473 1/20 0.37
CYP2A6 P11509 1/20 0.37
CTSA P10619 1/20 0.36
CYP2D6 P10635 2/20 0.36
MAOA P21397 1/20 0.36
MAPK1 P28482 1/20 0.36
ADRA1A P35348 1/20 0.36
SCN4A P35499 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
PDE3A Q14432 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15637371 0.83 CYP2A6 (0.56) TSHRCYP2A6
SCHEMBL4456546 0.80 AHR (0.64) AHRCNR2NOTUMIDO1CNR1
SCHEMBL15636896 0.79 CNR2 (0.41) AHRCNR2NOTUMIDO1CNR1
SCHEMBL4456479 0.78 AHR (0.45) AHRCNR2NOTUMIDO1CNR1
SCHEMBL1815223 0.76 GRIA1 (0.40) AHRCNR1TSHRCYP2A6CYP2D6
SCHEMBL31339486 0.75 AHR (0.42) AHRCNR2NOTUMIDO1CNR1
SCHEMBL440943 0.74 TSHR (0.52) CNR2NOTUMIDO1TSHRCYP2A6
SCHEMBL29489437 0.73 CYP2A6 (0.68) CNR2NOTUMIDO1TSHRCYP2A6
SCHEMBL1250242 0.73 CYP2A6 (0.68) CNR2NOTUMIDO1TSHRCYP2A6
SCHEMBL533595 0.72 CNR2 (0.46) CNR2NOTUMIDO1CNR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235595-B8 INTEGRIN-MEDIATED DRUG TARGETING BAYER SCHERING PHARMA AG (DE) 2009-10-07 EP claimed
EP-1235595-A2 INTEGRIN-MEDIATED DRUG TARGETING Bayer Aktiengesellschaft (DE) 2002-09-04 EP claimed
WO-2001017563-A2 INTEGRIN-MEDIATED DRUG TARGETING BAYER AKTIENGESELLSCHAFT (DE) 2001-03-15 WO claimed